Related Experiment Videos
[A research on the cholestasis caused by continuous endotoxemia]
M Nishida1, S Tamakuma, T Idei
1First Department of Surgery, National Defense Medical College, Tokorozawa, Japan.
Nihon Geka Gakkai Zasshi
|February 1, 1990
Summary
Endotoxins from gram-negative bacteria may cause jaundice in patients undergoing peptic surgery. Studies in rats show continuous endotoxemia significantly reduces bile output and increases bilirubin, suggesting a novel mechanism for intrahepatic cholestasis.
Area of Science:
- Hepatology
- Toxicology
- Surgical Infections
Context:
- Intrahepatic cholestasis is frequently observed in patients with prolonged infections post-peptic surgery, often without bile duct obstruction.
- Clinical analysis of 18 cases revealed high incidences of endotoxemia and gram-negative bacilli, suggesting a link between endotoxins and jaundice.
- Existing research lacks a clear understanding of the endotoxin-induced jaundice mechanism in non-shock conditions.
Purpose:
- To investigate the mechanism by which endotoxins may cause intrahepatic cholestasis and jaundice.
- To establish and validate an experimental rat model of persistent, low-dose endotoxemia for studying jaundice.
- To determine the effect of continuous endotoxemia on bile output, serum bilirubin, and liver blood flow.
Summary:
- An experimental model using continuous low-dose endotoxin infusion in rats was developed to mimic jaundice seen in surgical patients.
- The endotoxin-infused group exhibited significantly decreased bile output and elevated serum bilirubin levels compared to controls.
- Liver tissue blood flow and systemic blood pressure remained stable, indicating a non-shock condition where bile acid-independent flow was depressed by endotoxins.
Impact:
- This study provides a valuable non-shock model for investigating endotoxin-induced intrahepatic cholestasis.
- Findings suggest endotoxins directly impair bile acid-independent bile flow, contributing to jaundice in infected patients.
- The research may lead to new therapeutic strategies for managing cholestasis in critically ill patients with gram-negative infections.